HAL Université de Tours
Not a member yet
55851 research outputs found
Sort by
La place de l’Histoire du droit et des institutions dans les pensées libertaires
No full textInternational audienc
Rapid cell turnover to model adipocyte size distribution
No full textInternational audienceWhite adipose tissue, composed of adipocyte cells, primarily stores energy as lipid droplets. The size of adipocytes varies significantly within the tissue according to the amount of stored lipids. A striking observation is that the adipocyte size distribution is bimodal, and thus, this tissue is lacking a characteristic size. We propose a novel dynamical model, based on a partial differential equation, to represent the adipocyte size distribution. The model assumes continuous adipocyte growth, with a velocity dependent on cell radius and extracellular lipid availability, together with constant rates of cell recruitment and death. We prove the existence and local stability of a unique stationary solution for a broad range of growth velocity functions. Choosing a parcimonious formulation, we show that only three parameters are enough to describe adipocyte size distributions measurements in rats. These parameters are robustly estimated through approximate Bayesian computation, and the model demonstrates excellent agreement with experimental data. This mechanistic, three-parameter framework offers a new and interpretable approach to characterizing adipocyte size distributions
Enigma portal case: exceptional urinary crystals
No full textInternational audienceQuiz focusing on the cytological analysis of urine in a case of urinary tract infection caused by E. coli, and its management with ceftriaxone treatment
Experimental monitoring of polyethylene viscosity during rotomolding by ultrasonic nondestructive method
No full textInternational audienc
Prediction of inclisiran efficacy in patients with established atherosclerotic cardiovascular disease: the SIRIUS In-Silico modelling of cardiovascular outcomes
No full textInternational audienceAims: Inclisiran, an siRNA-targeting hepatic PCSK9 mRNA, reduces low-density lipoprotein cholesterol (LDL-C), but its effect on major adverse cardiovascular event (MACE) remains unconfirmed. The SIRIUS in-silico modelling program aimed to predict the efficacy of inclisiran on MACE in virtual patients with atherosclerotic cardiovascular disease (ASCVD).Methods: The SIRIUS simulation (NCT05974345) used a validated mechanistic model of ASCVD and lipid-lowering therapy (LLT) effects in a virtual population with established ASCVD and LDL-C ≥70 mg/dL. Each virtual patient served as their own control to compare inclisiran versus placebo as an adjunct to high-intensity statin therapy, alone or with ezetimibe over 5 years. The model did not account for non-adherence, recurrent events, or adverse effects.Results: Among 204 691 virtual patients, inclisiran was predicted to reduce LDL-C by 49.7% versus placebo (from 91.1 to 48.3 mg/dL). Relative to placebo, inclisiran was predicted to lower 5 years risk of 3-point MACE by 25.2% (11.3% vs. 14.9%), myocardial infarction by 34.8% (5.7% vs. 8.6%; HR 0.65), ischaemic stroke by 26% (2.6% vs. 3.4%; HR 0.74), and major adverse limb event by 34.1% (0.5% vs. 0.8%; HR 0.66). A 7.1% relative reduction of cardiovascular death was predicted (4.2% vs. 4.5%; HR 0.93).Conclusions: SIRIUS is the first in-silico simulation using a knowledge-based mechanistic model to predict the efficacy of LLT on cardiovascular outcomes in ASCVD. These findings offer early model-based prediction of inclisiran's potential cardiovascular benefit ahead of phase 3 outcome trials
Transports - Notion de voyageur; CJUE, 13 nov. 2025, aff. C-445/24, MS Amlin Insurance SE c/ (W)onderwer VZW
No full textInternational audienceUne association à but non lucratif, qui a conclu un contrat de voyage à forfait, en son nom mais pour le compte de ses membres est un voyageur au sens de la directive voyages à forfaitLa notion autonome de voyageur soit être interprétée largemen
MVMI: Multi-View Multi-Instance network for the detection of knee osteoarthritis
No full textInternational audienc
L’empowerment en santé : la révolution douce des associations de patients
No full textInternational audienc
Un dialogue qui ne dit pas son nom ? Formes, usages et limites du dialogue professionnel en PME
No full textde La Rochefoucauld, M., Chader, A. (2025). La Régulation Interne de L'usage de L'intelligence Artificielle Générative En Entreprise : Cas D'orange. Innovations, Pub. anticipées(0), I190-XXXII.International audienceÀ l’heure où les organisations sont invitées à « ouvrir des espaces de discussion sur le travail », le dialogue professionnel suscite un intérêt croissant en tant que levier de régulation, de reconnaissance et d’adaptation. Pourtant, ce concept demeure peu stabilisé scientifiquement, notamment dans les PME où les pratiques sont largement informelles. Cet article s’appuie sur une étude qualitative menée auprès de 11 PME françaises, au travers de 44 entretiens semi-directifs croisant les regards de quatre profils d’acteurs (salariés, managers, représentants du personnel, direction). L’objectif est de mieux comprendre comment le dialogue professionnel est défini, mis en œuvre et perçu dans les pratiques organisationnelles, et comment il s’articule – ou entre en tension – avec le dialogue social. Les résultats mettent en évidence une pluralité de représentations, une prédominance des formes informelles, et un besoin de structuration lisible. Le dialogue professionnel apparaît à la fois comme ressource de management, espace d’expression ou tentative d’innovation sociale, mais aussi comme un objet ambivalent dont la légitimité dépend de sa reconnaissance et de son articulation avec les formes de représentation collective